Healthcare provider profile · identity verified

Victoria A Rodriguez-Quick, MD

Internal Medicine · MCALLEN, TX · NPI 1033747456

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	225	101
Rosuvastatin Calcium	Rosuvastatin Calcium	208	101
Levothyroxine Sodium	Levothyroxine Sodium	152	65
Lisinopril	Lisinopril	144	58
Ozempic	Semaglutide	131	33
Metformin Hcl	Metformin Hcl	118	55
Amlodipine Besylate	Amlodipine Besylate	107	52
Gabapentin	Gabapentin	106	53
Losartan Potassium	Losartan Potassium	95	39
Jardiance	Empagliflozin	91	30
Metoprolol Succinate	Metoprolol Succinate	86	33
Fluticasone Propionate	Fluticasone Propionate	71	36
Famotidine	Famotidine	70	37
Tamsulosin Hcl	Tamsulosin Hcl	65	31
Omeprazole	Omeprazole	60	31
Alendronate Sodium	Alendronate Sodium	58	30
Trazodone Hcl	Trazodone Hcl	57	23
Olmesartan Medoxomil	Olmesartan Medoxomil	53	24
Albuterol Sulfate Hfa	Albuterol Sulfate	51	22
Hydralazine Hcl	Hydralazine Hcl	51	21
Meclizine Hcl	Meclizine Hcl	50	26
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	50	38
Tramadol Hcl	Tramadol Hcl	50	19
Escitalopram Oxalate	Escitalopram Oxalate	48	25
Farxiga	Dapagliflozin Propanediol	45	20
Baclofen	Baclofen	42	26
Furosemide	Furosemide	42	21
Clopidogrel	Clopidogrel Bisulfate	41	14
Metformin Hcl Er	Metformin Hcl	41	15
Montelukast Sodium	Montelukast Sodium	41	23
Nifedipine Er	Nifedipine	40	18
Sertraline Hcl	Sertraline Hcl	38	17
Ezetimibe	Ezetimibe	36	21
Pantoprazole Sodium	Pantoprazole Sodium	36	22
Memantine Hcl	Memantine Hcl	35	16
Diclofenac Sodium	Diclofenac Sodium	33	16
Donepezil Hcl	Donepezil Hcl	33	18
Metoprolol Tartrate	Metoprolol Tartrate	33	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	16
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	30	15
Alprazolam	Alprazolam	27	14
Hydrochlorothiazide	Hydrochlorothiazide	27	suppressed
Myrbetriq	Mirabegron	27	13
Januvia	Sitagliptin Phosphate	26	12
Pioglitazone Hcl	Pioglitazone Hcl	26	12
Simvastatin	Simvastatin	26	13
Tresiba Flextouch U-100	Insulin Degludec	26	suppressed
Finasteride	Finasteride	23	12
Oxybutynin Chloride Er	Oxybutynin Chloride	23	14
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Naproxen	Naproxen	20	15
Glipizide	Glipizide	19	suppressed
Ibuprofen	Ibuprofen	19	14
Mounjaro	Tirzepatide	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Prolia	Denosumab	17	15
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Pregabalin	Pregabalin	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Folic Acid	Folic Acid	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Icosapent Ethyl	Icosapent Ethyl	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	12
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Risperidone	Risperidone	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Gemtesa	Vibegron	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Synjardy	Empagliflozin/Metformin Hcl	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error